Corient Private Wealth
ESPR

Corient Private Wealth’s Esperion Therapeutics ESPR Stock Holding History

Corient Private Wealth’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.8K Buy
+11,821
New +$37.4K ﹤0.01% 2796
2025
Q2 		– Sell
-15,000
Closed -$21.6K – 2471
2025
Q1 		$21.6K Sell
15,000
-35,745
-70% -$65.9K ﹤0.01% 2254
2024
Q4 		$112K Sell
50,745
-108,702
-68% -$254K ﹤0.01% 2209
2024
Q3 		$263K Sell
159,447
-23,053
-13% -$46.5K ﹤0.01% 2070
2024
Q2 		$405K Buy
+182,500
New +$429K ﹤0.01% 1757
2023
Q2 		– Sell
-17,334
Closed -$27.6K – 2101
2023
Q1 		$27.6K Buy
+17,334
New +$89.5K ﹤0.01% 1964

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return